{
    "Clinical Trial ID": "NCT00258349",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Vorinostat +Trastuzumab",
        "  Trastuzumab: 6 mg/kg once on Day 1, infused over 90 minutes, every 3 weeks;",
        "  Vorinostat 200 mg of SAHA orally twice a day, daily for 14 days out of a 21-day cycle"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Not pregnant or nursing",
        "  Negative pregnancy test",
        "  Fertile patients must use effective contraception",
        "  No active or ongoing infection",
        "  No history of allergic reaction to compounds of similar chemical or biologic composition to vorinostat or other agents used in study",
        "  No psychiatric illness or social situation that would preclude study compliance",
        "  No other uncontrolled illness",
        "  More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin; 1 week for capecitabine) and recovered",
        "  More than 3 weeks since prior radiotherapy and recovered",
        "  Recovered from prior therapy",
        "  At least 2 weeks since prior valproic acid",
        "  More than 4 weeks since prior investigational agents",
        "  More than 4 weeks since prior lapatinib ditosylate",
        "  No concurrent combination antiretroviral therapy for HIV-positive patients",
        "  Measurable disease, defined as >= 1 unidimensionally measurable lesion > 20 mm by conventional techniques or > 10 mm by spiral CT scan",
        "  No other concurrent investigational agents",
        "  Concurrent bisphosphonates allowed provided therapy was initiated prior to study treatment",
        "  No other concurrent anticancer therapy",
        "  Recurrent or progressive disease while receiving prior trastuzumab (Herceptin) (with or without chemotherapy) OR relapsed within 3 months of last dose of prior adjuvant trastuzumab for metastatic disease",
        "  Histologically confirmed breast cancer",
        "  Must overexpress HER-2 gene",
        "  Metastatic or chest wall recurrent disease",
        "  Site of measurable disease must not have been irradiated (except chest wall recurrence treated with adjuvant radiation therapy)",
        "  No untreated brain metastases",
        "  Previously treated brain metastasis responsive to radiotherapy and/or surgery allowed provided the brain is not the sole site of measurable disease",
        "  ECOG 0-2",
        "  Absolute neutrophil count >= 1,500/mm^3",
        "  Platelet count >= 100,000/mm^3",
        "  Hemoglobin >= 9 g/dL",
        "  AST and ALT =< 2 times upper limit of normal",
        "  Bilirubin =< 1.5 mg/dL (3 mg/dL in the presence of Gilbert's disease provided direct bilirubin is normal)",
        "  Creatinine =< 1.5 mg/dL",
        "  LVEF normal by nuclear scan or echocardiogram",
        "  No evidence of PR prolongation or AV block by EKG",
        "  No symptomatic congestive heart failure",
        "  No unstable angina pectoris",
        "  No cardiac arrhythmia"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Response Rate",
        "  Tumor response is assessed by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.0. Response included complete response (CR) and partial response (PR). CR is defined as the disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum longest diameter.",
        "  Time frame: Tumor assessment was obtained at baseline, after 6 weeks (week 6 = last week of Cycle 2), and after every 4 cycles of therapy",
        "Results 1: ",
        "  Arm/Group Title: Vorinostat +Trastuzumab",
        "  Arm/Group Description: Trastuzumab: 6 mg/kg once on Day 1, infused over 90 minutes, every 3 weeks;",
        "  Vorinostat 200 mg of SAHA orally twice a day, daily for 14 days out of a 21-day cycle",
        "  Overall Number of Participants Analyzed: 10",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  0        (0 to 26)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 2/9 (22.22%)",
        "  Thrombocytopenia 2/9 (22.22%)",
        "  Dyspnea 0/9 (0.00%)"
    ]
}